Evaluating the effectiveness of low-dose oral switch therapy for uncomplicated streptococcal or enterococcal bloodstream infection: a retrospective cohort study
Abstract
Abstract Background Although oral switch therapy (OST) is increasingly recognized as a viable option for uncomplicated gram-positive bloodstream infections (GP-BSI), its optimal dosage remains unclear. In Japan, high-dose regimens of key oral antimicrobials, such as amoxicillin (1000 mg thrice daily) or levofloxacin (750 mg once daily), are not approved. This study investigated the effectiveness of low-dose OST for GP-BSI in a population with a low prevalence of obesity. Methods This retrospective, single-centre study involved patients aged ≥18 years with monomicrobial, uncomplicated BSI caused by ampicillin- or amoxicillin-susceptible Streptococcus or Enterococcus species treated between 2010 and 2023. Patients eligible for OST were identified on day 5 of microbiologically active therapy. Demographic, clinical, laboratory, and microbiological data were analysed. Using overlap weighting, we compared 90-day all-cause mortality between OST and intravenous therapy (IVT) only groups. Results A total of 172 patients (86 with OST and 86 with IVT only) were included. The median body mass index was 22.5 (interquartile range [IQR], 19.2–24.7), and the median duration of therapy was 14 days (IQR, 12–15 days). Common oral regimens included amoxicillin (n = 34, 39.5%), amoxicillin/clavulanate (n = 24, 27.9%), and levofloxacin (n = 12, 14.0%). No significant difference in 90-day all-cause mortality was observed between OST and IVT groups (odds ratio, 0.73; 95% confidence interval,…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 172 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.